
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics is a biopharmaceutical company with a promising pipeline of RNA therapeutics targeting severe genetic rare diseases such as cystic fibrosis and Leber congenital amaurosis type 10. The recent positive target engagement data and successful fundraising efforts have extended the company's operational runway, giving it the resources to continue development and potential commercialization of its therapies. However, the company faces significant competition in the biotech and pharmaceutical industries and has additional clinical and regulatory risks to consider. Upcoming potential catalysts, including data from its intrathecal delivery of AX-0422, may inform the development of future therapies and could have a significant impact on the stock.
Bears say
ProQR Therapeutics is facing several challenges that prevent it from being a profitable company in the near future. With its current negative cash flow and the potential need to raise debt or equity financing in the future, the company's financial stability is at risk. Additionally, the company's products face significant competition in the biotechnology and pharmaceutical industries, and there is no guarantee that its intellectual property will provide protection against competitors. These factors, along with potential legal expenses and regulatory risks, contribute to our negative outlook on the company's stock.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares